Colorcon starts No-Tox ink manufacturing at new UK facility
The additional capacity will provide customers with shorter lead times and reduced transportation costs.
Colorcon No-Tox Products, a leader in the design and manufacture of FDA and EU regulatory compliant specialty printing inks for direct and indirect contact with food, medical devices and pharmaceutical products has opened a new UK-based manufacturing facility to serve its growing customer base in Europe, the Middle East and Africa (EMEA).
With this new manufacturing capacity, Colorcon No-Tox is strengthening its presence in the European and UK markets and will provide its customers with shorter lead times and reduced transportation costs.
“We are excited to announce this important next step in our strategy to become an integral part of our customers’ supply chains,” said Simon Tasker, President, Colorcon Americas.
“Our new No-Tox plant in the UK, which is an extension of our existing pharmaceutical manufacturing plant in Dartford will allow us to serve our customers in increasingly better and more efficient ways by providing our high-quality regulatory compliant inks and coatings with close proximity to their markets and at lower transportation costs.”
David Bain, Managing Director, Colorcon Ltd added: “Our regional team is looking forward to supporting this next stage in the strategic market expansion of our Colorcon No-Tox specialty printing ink business. The plant will initially focus on regulatory compliant inks and coatings for direct and indirect food contact applications; such as those widely used in the plastic to paper straw conversion. The addition of medical and pharmaceutical inks and coatings will be extended through 2020.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance